{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:42:25Z","timestamp":1790991745371,"version":"4.1.0"},"reference-count":95,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,14]]},"DOI":"10.14797\/mdcvj.1068","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T10:59:51Z","timestamp":1647255591000},"page":"94-105","source":"Crossref","is-referenced-by-count":28,"title":["State-of-the-Art Treatments for Sarcoidosis"],"prefix":"10.14797","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1391-2925","authenticated-orcid":false,"given":"Ilias C.","family":"Papanikolaou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Antonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aggeliki","family":"Pandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"2","key":"key20220314065947_B1","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other G ranulomatous Disorders","volume":"16","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"8","key":"key20220314065947_B2","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"key20220314065947_B3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ccm.2015.08.008","article-title":"Cardiac Sarcoidosis","volume":"36","year":"2015","journal-title":"Clin Chest Med"},{"issue":"7","key":"key20220314065947_B4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study","volume":"131","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"key20220314065947_B5","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"key20220314065947_B6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","year":"2021","journal-title":"Thorax"},{"issue":"10","key":"key20220314065947_B7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.rmed.2012.01.013","article-title":"The treatment of pulmonary sarcoidosis","volume":"106","year":"2012","journal-title":"Respir Med"},{"issue":"11","key":"key20220314065947_B8","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"Japanese Circulation Society Joint Working Group. JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis\u3000- Digest Version","volume":"83","year":"2019","journal-title":"Circ J"},{"issue":"1","key":"key20220314065947_B9","article-title":"Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography\/Computed Tomography in the Assessment of Cardiac Sarcoidosis","volume":"11","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"key20220314065947_B10","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1002\/ehf2.12853","article-title":"Diagnosis of isolated cardiac sarcoidosis based on new guidelines","volume":"7","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"1","key":"key20220314065947_B11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of Mortality in Pulmonary Sarcoidosis","volume":"153","year":"2018","journal-title":"Chest"},{"issue":"5","key":"key20220314065947_B12","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.chest.2020.04.074","article-title":"Mixed Ventilatory Defects in Pulmonary Sarcoidosis: Prevalence and Clinical Features","volume":"158","year":"2020","journal-title":"Chest"},{"issue":"7","key":"key20220314065947_B13","first-page":"1305","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","year":"2014","journal-title":"Heart Rhythm"},{"issue":"6","key":"key20220314065947_B14","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","year":"2021","journal-title":"Eur Respir J"},{"issue":"4","key":"key20220314065947_B15","article-title":"Utility of FDG PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive Treatment in Cardiac Sarcoidosis","volume":"2","year":"2020","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"2","key":"key20220314065947_B16","first-page":"CD001114","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"2005","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"7515","key":"key20220314065947_B17","first-page":"526","article-title":"Treatment of sarcoidosis. Report of a controlled therapeutic trial","volume":"2","year":"1967","journal-title":"Lancet"},{"issue":"9","key":"key20220314065947_B18","first-page":"496","article-title":"Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study","volume":"87","year":"1987","journal-title":"N Y State J Med"},{"issue":"1","key":"key20220314065947_B19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1378\/chest.121.1.24","article-title":"Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function","volume":"121","year":"2002","journal-title":"Chest"},{"issue":"3","key":"key20220314065947_B20","first-page":"623","article-title":"Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy","volume":"111","year":"1997","journal-title":"Chest"},{"key":"key20220314065947_B21","first-page":"S31","article-title":"No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis","volume":"138S","year":"2018","journal-title":"Respir Med"},{"issue":"3","key":"key20220314065947_B22","first-page":"198","article-title":"Use of fluticasone in acute symptomatic pulmonary sarcoidosis","volume":"19","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"key20220314065947_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations","volume":"339","year":"2010","journal-title":"Am J Med Sci"},{"issue":"4","key":"key20220314065947_B24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1378\/chest.12-1060","article-title":"Acute pulmonary exacerbations of sarcoidosis","volume":"142","year":"2012","journal-title":"Chest"},{"key":"key20220314065947_B25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","year":"2017","journal-title":"Respir Med"},{"issue":"155","key":"key20220314065947_B26","doi-asserted-by":"crossref","first-page":"190145","DOI":"10.1183\/16000617.0145-2019","article-title":"Clinical phenotyping: role in treatment decisions in sarcoidosis","volume":"29","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"5","key":"key20220314065947_B27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide","volume":"19","year":"2013","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"key20220314065947_B28","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study","volume":"36","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"key20220314065947_B29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","year":"2013","journal-title":"Chest"},{"issue":"5","key":"key20220314065947_B30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.99.14511179","article-title":"Treatment of chronic sarcoidosis with an azathioprine\/prednisolone regimen","volume":"14","year":"1999","journal-title":"Eur Respir J"},{"issue":"5","key":"key20220314065947_B31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","year":"2011","journal-title":"Eur Respir J"},{"issue":"1","key":"key20220314065947_B32","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis","volume":"21","year":"2004","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"key20220314065947_B33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clpt.2004.01.016","article-title":"Peripheral neuropathy in patients treated with leflunomide","volume":"75","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"key20220314065947_B34","first-page":"167","article-title":"Leflunomide-induced interstitial lung disease (a systematic review)","volume":"30","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"key20220314065947_B35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajo.2016.06.045","article-title":"The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both","volume":"170","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"key20220314065947_B36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clindermatol.2007.03.011","article-title":"Evidence-based therapy for cutaneous sarcoidosis","volume":"25","year":"2007","journal-title":"Clin Dermatol"},{"issue":"5","key":"key20220314065947_B37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-111-5-437","article-title":"Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy","volume":"111","year":"1989","journal-title":"Ann Intern Med"},{"issue":"1","key":"key20220314065947_B38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"key20220314065947_B39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","article-title":"Efficacy of mycophenolate mofetil in sarcoidosis","volume":"108","year":"2014","journal-title":"Respir Med"},{"issue":"4","key":"key20220314065947_B40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.wnl.0000341278.26993.22","article-title":"Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil","volume":"72","year":"2009","journal-title":"Neurology"},{"issue":"24","key":"key20220314065947_B41","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil","volume":"87","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"key20220314065947_B42","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"key20220314065947_B43","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"key20220314065947_B44","first-page":"289","article-title":"Sarcoidosis Investigators. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"20","key":"key20220314065947_B45","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series","volume":"89","year":"2017","journal-title":"Neurology"},{"issue":"15","key":"key20220314065947_B46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"key20220314065947_B47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cardfail.2020.08.013","article-title":"Clinical and Imaging Response to Tumor Necrosis Factor Alpha Inhibitors in Treatment of Cardiac Sarcoidosis: A Multicenter Experience","volume":"27","year":"2021","journal-title":"J Card Fail"},{"issue":"4","key":"key20220314065947_B48","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s11845-015-1363-9","article-title":"Adalimumab for refractory pulmonary sarcoidosis","volume":"185","year":"2016","journal-title":"Ir J Med Sci"},{"issue":"5","key":"key20220314065947_B49","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"key20220314065947_B50","first-page":"121","article-title":"Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis","volume":"26","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"key20220314065947_B51","article-title":"Roflumilast (Daliresp\u00ae) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial","volume":"38","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"key20220314065947_B52","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archdermatol.2011.301","article-title":"Efficacy and safety of apremilast in chronic cutaneous sarcoidosis","volume":"148","year":"2012","journal-title":"Arch Dermatol"},{"issue":"5","key":"key20220314065947_B53","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","year":"2014","journal-title":"Eur Respir J"},{"issue":"5","key":"key20220314065947_B54","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis","volume":"159","year":"2021","journal-title":"Chest"},{"issue":"3","key":"key20220314065947_B55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00408-017-9994-4","article-title":"Repository corticotropin for Chronic Pulmonary Sarcoidosis","volume":"195","year":"2017","journal-title":"Lung"},{"issue":"2","key":"key20220314065947_B56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study","volume":"199","year":"2021","journal-title":"Lung"},{"issue":"10","key":"key20220314065947_B57","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.13760","article-title":"Epidemiology of cutaneous sarcoidosis, 1976-2013: a population-based study from Olmsted County, Minnesota","volume":"30","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3 Pt 1","key":"key20220314065947_B58","first-page":"487","article-title":"Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas","volume":"23","year":"1990","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"key20220314065947_B59","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","year":"2008","journal-title":"Eur Respir J"},{"issue":"4","key":"key20220314065947_B60","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1378\/chest.14-0015","article-title":"A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis","volume":"146","year":"2014","journal-title":"Chest"},{"issue":"1","key":"key20220314065947_B61","first-page":"26","article-title":"Management of ocular sarcoidosis","volume":"29","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"5","key":"key20220314065947_B62","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MCP.0000000000000400","article-title":"Current concepts regarding calcium metabolism and bone health in sarcoidosis","volume":"23","year":"2017","journal-title":"Curr Opin Pulm Med"},{"issue":"9","key":"key20220314065947_B63","article-title":"Assessment of the 2017 AHA\/ACC\/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis","volume":"12","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"14","key":"key20220314065947_B64","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"key20220314065947_B65","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy","volume":"16","year":"2019","journal-title":"Heart Rhythm"},{"issue":"2","key":"key20220314065947_B66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.hrthm.2008.10.039","article-title":"Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry","volume":"6","year":"2009","journal-title":"Heart Rhythm"},{"key":"key20220314065947_B67","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijcard.2016.10.101","article-title":"Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis","volume":"227","year":"2017","journal-title":"Int J Cardiol"},{"issue":"9","key":"key20220314065947_B68","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","year":"2001","journal-title":"Am J Cardiol"},{"issue":"6","key":"key20220314065947_B69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.md.0000145367.17934.75","article-title":"Cardiac sarcoidosis: a retrospective study of 41 cases","volume":"83","year":"2004","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"key20220314065947_B70","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chest.2016.08.1457","article-title":"Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival","volume":"151","year":"2017","journal-title":"Chest"},{"issue":"23","key":"key20220314065947_B71","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.2169\/internalmedicine.53.3120","article-title":"Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions","volume":"53","year":"2014","journal-title":"Intern Med"},{"issue":"18","key":"key20220314065947_B72","article-title":"Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis","volume":"8","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"key20220314065947_B73","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cardfail.2021.06.010","article-title":"Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent","volume":"27","year":"2021","journal-title":"J Card Fail"},{"issue":"3","key":"key20220314065947_B74","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.semarthrit.2019.11.004","article-title":"TNF-alpha inhibition for the treatment of cardiac sarcoidosis","volume":"50","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"key20220314065947_B75","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijcard.2018.11.131","article-title":"Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs","volume":"276","year":"2019","journal-title":"Int J Cardiol"},{"key":"key20220314065947_B76","article-title":"Management of Advanced Pulmonary Sarcoidosis","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"key20220314065947_B77","doi-asserted-by":"crossref","first-page":"1901747","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry","volume":"55","year":"2020","journal-title":"Eur Respir J"},{"issue":"2","key":"key20220314065947_B78","first-page":"184","article-title":"Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension","volume":"37","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"key20220314065947_B79","first-page":"234","article-title":"Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy","volume":"37","year":"2020","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"key20220314065947_B80","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1378\/chest.13-1766","article-title":"Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial","volume":"145","year":"2014","journal-title":"Chest"},{"key":"key20220314065947_B81","first-page":"S0012-3692(21)03613-8","article-title":"Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial","year":"2021","journal-title":"Chest"},{"issue":"2","key":"key20220314065947_B82","doi-asserted-by":"crossref","first-page":"2003358","DOI":"10.1183\/13993003.03358-2020","article-title":"Lung transplantation for sarcoidosis: outcome and prognostic factors","volume":"58","year":"2021","journal-title":"Eur Respir J"},{"key":"key20220314065947_B83","doi-asserted-by":"crossref","first-page":"2004538","DOI":"10.1183\/13993003.04538-2020","article-title":"INBUILD trial investigators. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"key20220314065947_B84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis","volume":"16","year":"2016","journal-title":"BMC Neurol"},{"issue":"11","key":"key20220314065947_B85","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis","volume":"74","year":"2017","journal-title":"JAMA Neurol"},{"issue":"16","key":"key20220314065947_B86","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/archinte.1997.00440370104011","article-title":"Diagnosis and management of neurological sarcoidosis","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"issue":"5","key":"key20220314065947_B87","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","year":"2017","journal-title":"J Neurol"},{"issue":"2","key":"key20220314065947_B88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/HCR.0000000000000307","article-title":"Efficacy of a Structured Exercise Program for Improving Functional Capacity and Quality of Life in Patients With Stage 3 and 4 Sarcoidosis: A RANDOMIZED CONTROLLED TRIAL","volume":"38","year":"2018","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"key20220314065947_B89","first-page":"1","article-title":"Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: A randomized controlled trial","volume":"77","year":"2020","journal-title":"Respir Med Res"},{"issue":"4","key":"key20220314065947_B90","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4187\/respcare.04312","article-title":"Effects of Inspiratory Muscle Training in Subjects With Sarcoidosis: A Randomized Controlled Clinical Trial","volume":"61","year":"2016","journal-title":"Respir Care"},{"issue":"5","key":"key20220314065947_B91","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue","volume":"133","year":"2008","journal-title":"Chest"},{"issue":"2","key":"key20220314065947_B92","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial","volume":"45","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"key20220314065947_B93","doi-asserted-by":"crossref","first-page":"105936","DOI":"10.1016\/j.rmed.2020.105936","article-title":"Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis","volume":"165","year":"2020","journal-title":"Respir Med"},{"issue":"3","key":"key20220314065947_B94","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11916-011-0180-8","article-title":"Sarcoidosis and small-fiber neuropathy","volume":"15","year":"2011","journal-title":"Curr Pain Headache Rep"},{"key":"key20220314065947_B95","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","year":"2017","journal-title":"Respir Med"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T11:01:19Z","timestamp":1647255679000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1068\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3,14]]}},"alternative-id":["10.14797\/mdcvj.1068"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1068","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}